Multimodal elucidation of choline metabolism in a murine glioma model using magnetic resonance spectroscopy and 11c-choline positron emission tomography

Cancer Research

Volumn 73, Issue 5, 2013, Pages 1470-1480

  Wehrl, Hans F ^a   Schwab, Julian ^a   Hasenbach, Kathy ^b,e   Reischl, Gerald ^a   Tabatabai, Ghazaleh ^b,e   Quintanilla Martinez, Leticia ^c   Jiru, Filip ^f   Chughtai, Kamila ^g   Kiss, Andras ^g   Cay, Funda ^a   Bukala, Daniel ^a   Heeren, Ron M A ^g   Pichler, Bernd J ^a   Sauter, Alexander W ^a,d  

^a Werner Siemens Imaging Center   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Departments of Pathology   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^g FOM INSTITUTE AMOLF   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CHOLINE C 11; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; GLIOSIS; HISTOLOGY; IMAGE ANALYSIS; INFLAMMATION; MALE; MASS SPECTROMETRY; METABOLIC PARAMETERS; METABOLISM; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION EQUIPMENT; TUMOR GROWTH; TUMOR VOLUME; VOLUMETRY;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GLIOMA; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84874912251     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2532     Document Type: Article

References (33)

1. (CBTRUS) CBTRotUS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2006 Central Brain Tumor Registry of the United States, Hinsdale, IL; 2010.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
3. Mazzoleni S, Galli R. Gliomagenesis: A game played by few players or a team effort? Front Biosci (Elite Ed) 2012;4:205-13.
4. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer 2011;11:835-48.
5. Michel V, Yuan Z, Ramsubir S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med (Maywood) 2006;231:490-504.
6. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, et al. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-98.
7. Boulanger Y, Labelle M, Khiat A. Role of phospholipase A(2) on the variations of the choline signal intensity observed by 1H magnetic resonance spectroscopy in brain diseases. Brain Res Brain Res Rev 2000;33:380-9.
8. Imani F, Boada FE, Lieberman FS, Davis DK, Deeb EL, Mountz JM. Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro- deoxyglucose positron emission tomography for assessment of brain tumor progression. J Neuroimaging 2012;22: 184-90.
9. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 2009;91:69-81.
10. Frati A, Pichierri A, Bastianello S, Raco A, Santoro A, Esposito V, et al. Frameless stereotactic cerebral biopsy: Our experience in 296 cases. Stereotact Funct Neurosurg 2011;89:234-45.
11. Doblas S, He T, Saunders D, Hoyle J, Smith N, Pye Q, et al. In vivo characterization of several rodent glioma models by (1) H MRS. NMR Biomed 2012;25:685-94.
12. Utriainen M, Komu M, Vuorinen V, Lehikoinen P, Sonninen P, Kurki T, et al. Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS. J Neurooncol 2003;62:329-38.
13. Wyss MT, Spaeth N, Biollaz G, Pahnke J, Alessi P, Trachsel E, et al. Uptake of 18F-fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis. J Nucl Med 2007;48:608-14.
14. Hara T, Kosaka N, Shinoura N, Kondo T. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997;38:842-7.
15. Gulyas B, Nyary I, Borbely K. FDG, MET or CHO? The quest for the optimal PET tracer for glioma imaging continues. Nat Clin Pract Neurol 2008;4:470-1.
16. Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, et al. First clinical experience with integrated whole-body PET/MR: Comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 2012;53:845-55.
17. Sauter AW, Wehrl HF, Kolb A, Judenhofer MS, Pichler BJ. Combined PET/MRI: One step further in multimodality imaging. Trends Mol Med 2010;16:508-15.
18. Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003;63:8996-9006.
19. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30:672-9.
20. Beckstead JH.Asimple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. J Histochem Cytochem 1994;42:1127-34.
21. Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008;29:1176-82.
22. Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed 1997;10:2-12.
23. Usenius JP, Vainio P, Hernesniemi J, Kauppinen RA. Choline-containing compounds in human astrocytomas studied by 1H NMR spectroscopy in vivo and in vitro. J Neurochem 1994;63:1538-43.
24. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989;11:47-63.
25. Cohen BM, Renshaw PF, Stoll AL, Wurtman RJ, Yurgelun-Todd D, Babb SM. Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. JAMA 1995;274: 902-7.
26. Toft PB, Leth H, Lou HC, Pryds O, Henriksen O. Metabolite concentrations in the developing brain estimated with proton MR spectroscopy. J Magn Reson Imaging 1994;4:674-80.
27. Lee SG, Kim K, Kegelman TP, Dash R, Das SK, Choi JK, et al. Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity. Cancer Res 2011;71:6514-23.
28. Behrens PF, Ostertag CB, Warnke PC. Regional cerebral blood flow in peritumoral brain edema during dexamethasone treatment: A xenonenhanced computed tomographic study. Neurosurgery 1998;43: 235-40.
29. Kuhmonen J, Sivenius J, Riekkinen PJ Sr, Kauppinen RA. Decrease in brain choline-containing compounds following a short period of global ischemia in gerbils as detected by 1H NMR spectroscopy in vivo. NMR Biomed 1994;7: 231-6.
30. Rommel D, Bol A, Abarca-Quinones J, Peeters F, Robert A, Labar D, et al. Rodent rhabdomyosarcoma: Comparison between total choline concentration at H-MRS and [18F]-fluoromethylcholine uptake at PET using accurate methods for collecting data. Mol Imaging Biol 2010;12:415-23.
31. Shimizu H, Kumabe T, Shirane R, Yoshimoto T. Correlation between choline level measured by protonMRspectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol 2000;21:659-65.
32. Rand SD, Prost R, Haughton V, Mark L, Strainer J, Johansen J, et al. Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol 1997;18:1695-704.
33. Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, et al. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol 2010;12:1152-61.